"Cancer cell Plasticity in Melanoma" lab, Centre de Recherche en Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon1, 69008, Lyon, France.
Fondation Synergie Lyon Cancer, Plateforme de bio-informatique Gilles Thomas, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, 69008, Lyon, France.
Oncogene. 2024 May;43(20):1489-1505. doi: 10.1038/s41388-024-03010-7. Epub 2024 Mar 22.
Cell plasticity sustains intra-tumor heterogeneity and treatment resistance in melanoma. Deciphering the transcriptional mechanisms governing reversible phenotypic transitions between proliferative/differentiated and invasive/stem-like states is required. Expression of the ZEB1 transcription factor is frequently activated in melanoma, where it fosters adaptive resistance to targeted therapies. Here, we performed a genome-wide characterization of ZEB1 transcriptional targets, by combining ChIP-sequencing and RNA-sequencing, upon phenotype switching in melanoma models. We identified and validated ZEB1 binding peaks in the promoter of key lineage-specific genes crucial for melanoma cell identity. Mechanistically, ZEB1 negatively regulates SOX10-MITF dependent proliferative/melanocytic programs and positively regulates AP-1 driven invasive and stem-like programs. Comparative analyses with breast carcinoma cells revealed lineage-specific ZEB1 binding, leading to the design of a more reliable melanoma-specific ZEB1 regulon. We then developed single-cell spatial multiplexed analyses to characterize melanoma cell states intra-tumoral heterogeneity in human melanoma samples. Combined with scRNA-Seq analyses, our findings confirmed increased ZEB1 expression in Neural-Crest-like cells and mesenchymal cells, underscoring its significance in vivo in both populations. Overall, our results define ZEB1 as a major transcriptional regulator of cell states transitions and provide a better understanding of lineage-specific transcriptional programs sustaining intra-tumor heterogeneity in melanoma.
细胞可塑性维持黑色素瘤中的肿瘤内异质性和治疗耐药性。需要阐明调节增殖/分化和侵袭/干细胞样状态之间可逆表型转变的转录机制。ZEB1 转录因子的表达在黑色素瘤中经常被激活,它促进了对靶向治疗的适应性耐药。在这里,我们通过在黑色素瘤模型中的表型转换,结合 ChIP-seq 和 RNA-seq,对 ZEB1 转录靶点进行了全基因组特征分析。我们鉴定并验证了关键谱系特异性基因启动子中的 ZEB1 结合峰,这些基因对黑色素瘤细胞身份至关重要。从机制上讲,ZEB1 负调控 SOX10-MITF 依赖性增殖/黑素细胞程序,并正调控 AP-1 驱动的侵袭和干细胞样程序。与乳腺癌细胞的比较分析揭示了谱系特异性的 ZEB1 结合,从而设计了一种更可靠的黑色素瘤特异性 ZEB1 调控网络。然后,我们开发了单细胞空间多重分析来描绘人类黑色素瘤样本中肿瘤内黑色素瘤细胞状态的异质性。结合 scRNA-Seq 分析,我们的发现证实了神经嵴样细胞和间充质细胞中 ZEB1 表达增加,强调了其在这两个群体中的体内重要性。总的来说,我们的研究结果将 ZEB1 定义为细胞状态转变的主要转录调节剂,并提供了对黑色素瘤中肿瘤内异质性维持的谱系特异性转录程序的更好理解。